Risk of subsequent gliomas and meningiomas among 69,460 5-year survivors of childhood and adolescent cancer in Europe: the PanCareSurFup study

  1. Heymer, Emma J.
  2. Hawkins, Michael M.
  3. Winter, David L.
  4. Teepen, Jop ORCID logo
  5. Sunguc, Ceren
  6. Ronckers, Cécile M. ORCID logo
  7. ALLODJI, RODRIGUE ORCID logo
  8. Alessi, Daniela
  9. Sugden, Elaine
  10. Belle, Fabiën N.
  11. Bagnasco, Francesca
  12. Byrne, Julianne
  13. Bárdi, Edit
  14. Garwicz, Stanislaw
  15. Grabow, Desiree
  16. Jankovic, Momcilo
  17. Kaatsch, Peter
  18. Kaiser, Melanie
  19. Michel, Gisela ORCID logo
  20. Schindera, Christina ORCID logo
  21. Haddy, Nadia
  22. Journy, Neige
  23. Česen Mazić, Maja
  24. Skinner, Roderick
  25. Kok, Judith L.
  26. Gunnes, Maria W.
  27. Wiebe, Thomas
  28. Sacerdote, Carlotta
  29. MAULE, MILENA MARIA ORCID logo
  30. Terenziani, Monica
  31. Jakab, Zsuzsanna
  32. Winther, Jeanette Falck ORCID logo
  33. Lähteenmäki, Päivi Maria ORCID logo
  34. Zadravec Zaletel, Lorna
  35. Haupt, Riccardo
  36. Kuehni, Claudia E. ORCID logo
  37. Kremer, Leontien C.
  38. de Vathaire, Florent
  39. Hjorth, Lars ORCID logo
  40. Reulen, Raoul ORCID logo

Download
41416_2024_Article_2577.pdf 756,15KB
WeightNameValue
1000 Titel
  • Risk of subsequent gliomas and meningiomas among 69,460 5-year survivors of childhood and adolescent cancer in Europe: the PanCareSurFup study
1000 Autor/in
  1. Heymer, Emma J. |
  2. Hawkins, Michael M. |
  3. Winter, David L. |
  4. Teepen, Jop |
  5. Sunguc, Ceren |
  6. Ronckers, Cécile M. |
  7. ALLODJI, RODRIGUE |
  8. Alessi, Daniela |
  9. Sugden, Elaine |
  10. Belle, Fabiën N. |
  11. Bagnasco, Francesca |
  12. Byrne, Julianne |
  13. Bárdi, Edit |
  14. Garwicz, Stanislaw |
  15. Grabow, Desiree |
  16. Jankovic, Momcilo |
  17. Kaatsch, Peter |
  18. Kaiser, Melanie |
  19. Michel, Gisela |
  20. Schindera, Christina |
  21. Haddy, Nadia |
  22. Journy, Neige |
  23. Česen Mazić, Maja |
  24. Skinner, Roderick |
  25. Kok, Judith L. |
  26. Gunnes, Maria W. |
  27. Wiebe, Thomas |
  28. Sacerdote, Carlotta |
  29. MAULE, MILENA MARIA |
  30. Terenziani, Monica |
  31. Jakab, Zsuzsanna |
  32. Winther, Jeanette Falck |
  33. Lähteenmäki, Päivi Maria |
  34. Zadravec Zaletel, Lorna |
  35. Haupt, Riccardo |
  36. Kuehni, Claudia E. |
  37. Kremer, Leontien C. |
  38. de Vathaire, Florent |
  39. Hjorth, Lars |
  40. Reulen, Raoul |
1000 Verlag Nature Publishing Group UK
1000 Erscheinungsjahr 2024
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2024-01-19
1000 Erschienen in
1000 Quellenangabe
  • 130(6):976-986
1000 Copyrightjahr
  • 2024
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1038/s41416-024-02577-y |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10951281/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • <jats:title>Abstract</jats:title><jats:sec> <jats:title>Background</jats:title> <jats:p>Childhood cancer survivors are at risk of subsequent gliomas and meningiomas, but the risks beyond age 40 years are uncertain. We quantified these risks in the largest ever cohort.</jats:p> </jats:sec><jats:sec> <jats:title>Methods</jats:title> <jats:p>Using data from 69,460 5-year childhood cancer survivors (diagnosed 1940–2008), across Europe, standardized incidence ratios (SIRs) and cumulative incidence were calculated.</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>In total, 279 glioma and 761 meningioma were identified. CNS tumour (SIR: 16.2, 95% CI: 13.7, 19.2) and leukaemia (SIR: 11.2, 95% CI: 8.8, 14.2) survivors were at greatest risk of glioma. The SIR for CNS tumour survivors was still 4.3-fold after age 50 (95% CI: 1.9, 9.6), and for leukaemia survivors still 10.2-fold after age 40 (95% CI: 4.9, 21.4). Following cranial radiotherapy (CRT), the cumulative incidence of a glioma in CNS tumour survivors was 2.7%, 3.7% and 5.0% by ages 40, 50 and 60, respectively, whilst for leukaemia this was 1.2% and 1.7% by ages 40 and 50. The cumulative incidence of a meningioma after CRT in CNS tumour survivors doubled from 5.9% to 12.5% between ages 40 and 60, and in leukaemia survivors increased from 5.8% to 10.2% between ages 40 and 50.</jats:p> </jats:sec><jats:sec> <jats:title>Discussion</jats:title> <jats:p>Clinicians following up survivors should be aware that the substantial risks of meningioma and glioma following CRT are sustained beyond age 40 and be vigilant for symptoms.</jats:p> </jats:sec>
1000 Sacherschließung
lokal Adolescent [MeSH]
lokal /631/67/2324
lokal Survivors [MeSH]
lokal Adult [MeSH]
lokal Meningeal Neoplasms/epidemiology [MeSH]
lokal Central Nervous System Neoplasms/epidemiology [MeSH]
lokal Humans [MeSH]
lokal Incidence [MeSH]
lokal Middle Aged [MeSH]
lokal Risk Factors [MeSH]
lokal /631/67/2332
lokal Leukemia/epidemiology [MeSH]
lokal Europe/epidemiology [MeSH]
lokal Meningioma/complications [MeSH]
lokal Neoplasms, Second Primary/epidemiology [MeSH]
lokal /692/308/174
lokal Article
lokal /692/499
lokal Meningioma/etiology [MeSH]
lokal /631/67/1922
lokal Neoplasms, Second Primary/etiology [MeSH]
lokal Glioma/epidemiology [MeSH]
lokal article
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/SGV5bWVyLCBFbW1hIEou|https://frl.publisso.de/adhoc/uri/SGF3a2lucywgTWljaGFlbCBNLg==|https://frl.publisso.de/adhoc/uri/V2ludGVyLCBEYXZpZCBMLg==|https://orcid.org/0000-0002-2647-2677|https://frl.publisso.de/adhoc/uri/U3VuZ3VjLCBDZXJlbg==|https://orcid.org/0000-0003-3524-4657|https://orcid.org/0000-0002-1895-8415|https://frl.publisso.de/adhoc/uri/QWxlc3NpLCBEYW5pZWxh|https://frl.publisso.de/adhoc/uri/U3VnZGVuLCBFbGFpbmU=|https://frl.publisso.de/adhoc/uri/QmVsbGUsIEZhYmnDq24gTi4=|https://frl.publisso.de/adhoc/uri/QmFnbmFzY28sIEZyYW5jZXNjYQ==|https://frl.publisso.de/adhoc/uri/QnlybmUsIEp1bGlhbm5l|https://frl.publisso.de/adhoc/uri/QsOhcmRpLCBFZGl0|https://frl.publisso.de/adhoc/uri/R2Fyd2ljeiwgU3RhbmlzbGF3|https://frl.publisso.de/adhoc/uri/R3JhYm93LCBEZXNpcmVl|https://frl.publisso.de/adhoc/uri/SmFua292aWMsIE1vbWNpbG8=|https://frl.publisso.de/adhoc/uri/S2FhdHNjaCwgUGV0ZXI=|https://frl.publisso.de/adhoc/uri/S2Fpc2VyLCBNZWxhbmll|https://orcid.org/0000-0002-9589-0928|https://orcid.org/0000-0002-4511-287X|https://frl.publisso.de/adhoc/uri/SGFkZHksIE5hZGlh|https://frl.publisso.de/adhoc/uri/Sm91cm55LCBOZWlnZQ==|https://frl.publisso.de/adhoc/uri/xIxlc2VuIE1hemnEhywgTWFqYQ==|https://frl.publisso.de/adhoc/uri/U2tpbm5lciwgUm9kZXJpY2s=|https://frl.publisso.de/adhoc/uri/S29rLCBKdWRpdGggTC4=|https://frl.publisso.de/adhoc/uri/R3VubmVzLCBNYXJpYSBXLg==|https://frl.publisso.de/adhoc/uri/V2llYmUsIFRob21hcw==|https://frl.publisso.de/adhoc/uri/U2FjZXJkb3RlLCBDYXJsb3R0YQ==|https://orcid.org/0000-0003-2142-1288|https://frl.publisso.de/adhoc/uri/VGVyZW56aWFuaSwgTW9uaWNh|https://frl.publisso.de/adhoc/uri/SmFrYWIsIFpzdXpzYW5uYQ==|https://orcid.org/0000-0002-3440-5108|https://orcid.org/0000-0002-5500-9606|https://frl.publisso.de/adhoc/uri/WmFkcmF2ZWMgWmFsZXRlbCwgTG9ybmE=|https://frl.publisso.de/adhoc/uri/SGF1cHQsIFJpY2NhcmRv|https://orcid.org/0000-0001-8957-2002|https://frl.publisso.de/adhoc/uri/S3JlbWVyLCBMZW9udGllbiBDLg==|https://frl.publisso.de/adhoc/uri/ZGUgVmF0aGFpcmUsIEZsb3JlbnQ=|https://orcid.org/0000-0002-8302-7174|https://orcid.org/0000-0002-7328-0467
1000 Hinweis
  • DeepGreen-ID: 7607ac5cc13240c6a498c2f9771d3967 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Förderer
  1. FP7 Health |
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer FP7 Health |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6493009.rdf
1000 Erstellt am 2025-02-03T19:28:27.377+0100
1000 Erstellt von 322
1000 beschreibt frl:6493009
1000 Zuletzt bearbeitet 2025-09-12T08:32:08.284+0200
1000 Objekt bearb. Fri Sep 12 08:32:08 CEST 2025
1000 Vgl. frl:6493009
1000 Oai Id
  1. oai:frl.publisso.de:frl:6493009 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source